ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

394
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
Refresh
bearishWuxi Biologics
23 Jan 2024 09:37

Wuxi Biologics (2269.HK) - Dramatic Changes in Management Forecasts Fail to Bring Back Confidence

Here are some new business updates: There are concerns about the size of the newly added orders last December, which may not deliver expected...

Logo
548 Views
Share
bullishWuxi Biologics
17 Jan 2024 19:34Broker

WuXi Biologics (2269 HK) - On the Road to Recovery

WuXi Bio recently announced better-than-expected number of projects signed in 2023 despite the challenging macro environment in the global...

Logo
169 Views
Share
bearishWuxi Biologics
08 Jan 2024 05:10

FXI Rebalance Preview: Two Potential Changes in March

There could be 2 changes for the FXI in March with CGN Power and Yankuang Energy replacing CR Beer and Wuxi Bio. Impact on the potential adds is...

Logo
407 Views
Share
bearishWuxi Biologics
12 Dec 2023 09:47

Wuxi Biologics (2269.HK) - The Business Update Has Torn Away the Last Fig Leaf

Even though WuXi Bio launches US$600 million share repurchase, share price doesn't stop falling.Obviously, recent business update has changed...

Logo
675 Views
Share
x